

Sevion Therapeutics, Inc.  
Form 8-K  
February 19, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): February 18, 2015

Sevion Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)



**Item 2.02. Results of Operations and Financial Condition.**

On February 18, 2015, Sevion Therapeutics, Inc., a Delaware corporation, (the “Company”), issued a press release to report the Company’s financial results for the fiscal quarter ended December 31, 2014. The full text of the press release is attached to this current report on Form 8-K as Exhibit 99.1.

The information in this Item 2.02 and in any exhibits referred to herein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

Exhibit No. Description

99.1 Press Release of Sevion Therapeutics, Inc. dated February 18, 2015

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SEVION  
THERAPEUTICS,  
INC.**

Dated: February 18, 2015 By: /s/ David Rector  
Name: David  
Rector  
Title: Chief  
Executive Officer